Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 11, 2014, Pages 2439-2446

  Russo, Alessia ^a,b   Modica, Federica ^a,b   Guarrera, Simonetta ^a,b   Fiorito, Giovanni ^a,b   Pardini, Barbara ^a,b   Viberti, Clara ^a,b   Allione, Alessandra ^a,b   Critelli, Rossana ^b,c   Bosio, Andrea ^d   Casetta, Giovanni ^d   Cucchiarale, Giuseppina ^e   Destefanis, Paolo ^d   Gontero, Paolo ^d   Rolle, Luigi ^d   Zitella, Andrea ^d   Fontana, Dario ^d   Frea, Bruno ^d   Vineis, Paolo ^c,f   Sacerdote, Carlotta ^g   Matullo, Giuseppe ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Human Genetics Foundation   (Italy)

^d CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^e Clinica Cellini   (Italy)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g Cancer Epidemiology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CELL DNA;

AGED; ARTICLE; BCG VACCINATION; BLADDER CANCER; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DISEASE ASSOCIATION; FOLLOW UP; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TELOMERE; TELOMERE SHORTENING; BLADDER TUMOR; CASE CONTROL STUDY; FEMALE; GENETICS; MORTALITY; PATHOLOGY; PROGNOSIS;

AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; PROGNOSIS; TELOMERE; TELOMERE SHORTENING; URINARY BLADDER NEOPLASMS;

EID: 84920146655     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0228     Document Type: Article

References (30)

1. de Lange T. Protection of mammalian telomeres. Oncogene 2002;21:532-40.
2. Harley CB. Telomeres and aging. In:Blackburn EH, Greider CW, editors. Telomeres. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1995. p. 247-63.
3. Calado RT, Young NS. Telomere diseases. N Engl J Med 2009;361:2353-65.
4. Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, Dunning AM, et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS ONE 2011;6:e20466.
5. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005;26:1263-71.
6. McGrath M, Wong JY, Michaud D, Hunter DJ, De Vivo I. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2007;16:815-9.
7. Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 2003;95:1211-8.
8. Cherkas LF, Aviv A, Valdes AM, Hunkin JL, Gardner JP, Surdulescu GL, et al. The effects of social status on biological aging as measured by white-blood-cell telomere length. Aging Cell 2006;5:361-5.
9. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003;361:393-5.
10. Jeon HS, Choi YY, Choi JE, Lee WK, Lee E, Yoo SS, et al. Telomere length of tumor tissues and survival in patients with early stage non-small cell lung cancer. Mol Carcinog 2014;53:272-9.
11. Weischer M, Nordestgaard BG, Cawthon RM, Freiberg JJ, Tybjaerg-Hansen A, Bojesen SE. Short telomere length, cancer survival, and cancer risk in 47102 individuals. J Natl Cancer Inst 2013;105:459-68.
12. Ricceri F, Guarrera S, Sacerdote C, Polidoro S, Allione A, Fontana D, et al. ERCC1 haplotypes modify bladder cancer risk: a case-control study. DNA Repair (Amst) 2010;9:191-200.
13. Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, et al. Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy. Int J Cancer 2013;133:2004-9.
14. Zee RY, Michaud SE, Germer S, Ridker PM. Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. Clin Chim Acta 2009;403:139-41.
15. Tarone RE. Tests for trend in life table analysis. Biometrika 1975;62:679-90.
16. Team RDC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
17. Therneau TM. A package for survival analysis in S. Rochester, MN: Mayo Foundation; 1999.
18. Willeit P, Willeit J, Kloss-Brandstatter A, Kronenberg F, Kiechl S. Fifteen-year follow-up of association between telomere length and incident cancer and cancer mortality. JAMA 2011;306:42-4.
19. Wu KD, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B, Moore MA. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 2003;101:4982-9.
20. Jebaraj BM, Kienle D, Lechel A, Mertens D, Heuberger M, Ott G, et al. Telomere length in mantle cell lymphoma. Blood 2013;121:1184-7.
21. Diker-Cohen T, Uziel O, Szyper-Kravitz M, Shapira H, Natur A, Lahav M. The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms. Leuk Lymphoma 2013;54:2023-9.
22. Lee JJ, Nam CE, Cho SH, Park KS, Chung IJ, Kim HJ. Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy. Ann Hematol 2003;82:492-5.
23. Szyper-Kravitz M, Uziel O, Shapiro H, Radnay J, Katz T, Rowe JM, et al. Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34B haematopoietic cells and may prevent telomere attrition after chemotherapy. Br J Haematol 2003;120:329-36.
24. Unryn BM, Hao D, Gluck S, Riabowol KT. Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res 2006;12:6345-50.
25. Yoon SY, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, et al. Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity. Acta Haematol 2007;118:30-7.
26. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 2010;116:1899-907.
27. Friedrich U, Griese E, Schwab M, Fritz P, Thon K, Klotz U. Telomere length in different tissues of elderly patients. Mech Ageing Dev 2000;119:89-99.
28. Okuda K, Bardeguez A, Gardner JP, Rodriguez P, Ganesh V, Kimura M, et al. Telomere length in the newborn. Pediatr Res 2002;52:377-81.
29. Youngren K, Jeanclos E, Aviv H, Kimura M, Stock J, Hanna M, et al. Synchrony in telomere length of the human fetus. Hum Genet 1998;102:640-3.
30. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-41.